Novel Strategies for the Reversal of Cancer Cell Immortality
ISEF · 2023 Biomedical and Health Sciences Second Award
Overview
Glioblastoma (GBM) is the most common malignant adult brain tumor. With minimal clinical innovation, the prognosis for GBM patients remains grim. However, there is a commonality between 83% of GBMs: Telomerase Reverse Transcriptase promoter (TERTp) mutations. TERT, the catalytic component of telomerase, is responsible for telomere elongation and maintenance. The TERTp mutation creates a de novo ETS motif, allowing the GA-binding protein (GABP) transcription factor complex to specifically bind and reactivate the mutant allele. While direct targeting of telomerase has proven broadly toxic, targeting GABP to silence expression from the mutant TERTp is a potential alternative. However, direct small-molecule inhibition of transcription factors like GABP is challenging. To overcome this therapeutic barrier, I designed, engineered, and evaluated a GABPB1L transactivation-domain-null dominant-negative (B1-DN) transgene. I hypothesize that the B1-DN will sterically displace wildtype GABPB1L from the mutant TERTp, resulting in loss of TERT expression. Indeed, the B1-DN reduced TERT expression by up to 75% in TERTp mutant GBM, melanoma, and bladder cancer cell lines, but not in TERTp wildtype cells. This inhibitory effect was sustained throughout a 60-day time course, shortening telomeres throughout. Furthermore, since I have determined that GABP is a regulator of the mutant TERTp across 16 distinct cancer types, this B1-DN could eventually be valuable to the treatment of more than a million patients diagnosed with TERTp mutant tumors per year. Studies investigating the use of replicating retroviral vectors as a clinically relevant means to deliver the B1-DN are ongoing. In summary, this transgene may be able to reverse tumor cell immortality across all TERTp mutant cancers.
Awards (1)
- Second Award of $2,000 $2,000
Competition history
- ISEF 2023
Resources
Related projects
ISEF · 2024
Grand Theft Transcription Factor: Reversing Tumor Cell Immortality by Transcription Factor Relocalization
ISEF · 2025
Molecular Arsonists: Degrading Oncogenic Transcription Factors to Reverse Tumor Cell Immortality
ISEF · 2026
Protein Assassins: Screening for Improved Degraders to Reverse Tumor Immortality
ISEF · 2014
The Biological Function of Telomerase in the Discontinuation of Cancer Immortality
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair